-
公开(公告)号:WO2007109080A3
公开(公告)日:2007-11-15
申请号:PCT/US2007006493
申请日:2007-03-14
Applicant: VERTEX PHARMA , PERNI ROBERT B , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , TANOURY GERALD J , BENNANI YOUSSEF , ZLOKARNIK GREGOR , MALTAIS FRANCOIS
Inventor: PERNI ROBERT B , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , TANOURY GERALD J , BENNANI YOUSSEF , ZLOKARNIK GREGOR , MALTAIS FRANCOIS
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
CPC classification number: C07C231/20 , C07B2200/05 , C07B2200/07 , C07C237/04 , C07C2601/02 , C07D209/52 , C07D301/14 , C07D303/48 , C07D401/14 , C07D403/12 , C07D403/14 , C07D498/10 , C07K5/0202 , C07K7/02
Abstract: A deuterated a-ketoamido steric specific compound of the formula (I), wherein D denotes a deuterium atom on a steric specific carbon atom.
Abstract translation: 式(I)的氘代α-酮酰胺基空间特异性化合物,其中D表示空间特异性碳原子上的氘原子。
-
公开(公告)号:NZ571280A
公开(公告)日:2011-10-28
申请号:NZ57128007
申请日:2007-03-14
Applicant: VERTEX PHARMA
Inventor: PERNI ROBERT B , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , TANOURY GERALD J , BENNANI YOUSSEF , ZLOKARNIK GREGOR , MALTAIS FRANCOIS
IPC: C07D209/52 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C231/20 , C07C237/04 , C07D403/12 , C07D403/14 , C07D498/10
Abstract: Disclosed is a keto-enriched alpha-ketoamido compound represented by general formula (I) wherein D is a deuterium atom. Also disclosed is the use of the compounds of formula (I) for treating hepatitis C virus (HCV) infection or a condition mediated by HCV protease
-
公开(公告)号:AU2007227544A1
公开(公告)日:2007-09-27
申请号:AU2007227544
申请日:2007-03-14
Applicant: VERTEX PHARMA
Inventor: PERNI ROBERT B , JUNG YOUNG CHUN , TANOURY GERALD J , CHEN MINZHANG , FORSLUND RAYMOND E , BENNANI YOUSSEF , MALTAIS FRANCOIS , ZLOKARNIK GREGOR
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
Abstract: This invention relates to a process for preparing a compound of Formula 1 wherein: the carbon atoms alpha and beta to the carboxy group are stereocenters; R 1 is independently H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; R' 1 is deuterium such that the deuterium enrichment is at least 50%; R' 2 is -NHR 2 or -OE; R 2 is H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; and E is C 1-6 alkyl or benzyl; wherein the process comprises the steps of: a) forming a salt of a compound of Formula 1, and b) crystallizing said salt to give a compound of greater than 55% enantiomeric excess.
-
公开(公告)号:MX2008011868A
公开(公告)日:2008-12-15
申请号:MX2008011868
申请日:2007-03-14
Applicant: VERTEX PHARMA
Inventor: PERNI ROBERT B , MALTAIS FRANCOIS , TANOURY GERALD J , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , BENNANI YOUSSEF , ZLOKARNIK GREGOR
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
Abstract: Se describe un compuesto específico de (-cetoamido estérico deuterado de la Fórmula (I), en donde D denota un átomo de deuterio sobre un átomo de carbono específico, estérico.
-
公开(公告)号:AU2007227544B2
公开(公告)日:2012-11-01
申请号:AU2007227544
申请日:2007-03-14
Applicant: VERTEX PHARMA
Inventor: CHEN MINZHANG , PERNI ROBERT B , ZLOKARNIK GREGOR , TANOURY GERALD J , JUNG YOUNG CHUN , FORSLUND RAYMOND E , BENNANI YOUSSEF , MALTAIS FRANCOIS
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
Abstract: A deuterated α-ketoamido steric specific compound of the formula (I), wherein D denotes a deuterium atom on a steric specific carbon atom.
-
公开(公告)号:BRPI0709567A2
公开(公告)日:2011-07-12
申请号:BRPI0709567
申请日:2007-03-14
Applicant: VERTEX PHARMA
Inventor: PERNI ROBERT B , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , TANOURY GERALD J , BENNANI YOUSSEF , ZLOKARNIK GREGOR , MALTAIS FRANCOIS
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
Abstract: This invention relates to a process for preparing a compound of Formula 1 wherein: the carbon atoms alpha and beta to the carboxy group are stereocenters; R 1 is independently H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; R' 1 is deuterium such that the deuterium enrichment is at least 50%; R' 2 is -NHR 2 or -OE; R 2 is H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; and E is C 1-6 alkyl or benzyl; wherein the process comprises the steps of: a) forming a salt of a compound of Formula 1, and b) crystallizing said salt to give a compound of greater than 55% enantiomeric excess.
-
公开(公告)号:AR059917A1
公开(公告)日:2008-05-07
申请号:ARP070101078
申请日:2007-03-16
Applicant: VERTEX PHARMA
Inventor: PERNI ROBERT B , BENNANI YOUSSEF , CHEN MINZHANG , JUNG YOUNG CHUN , FORSLUND RAYMOND E , MALTAIS FRANCOIS
IPC: C07D403/12 , A61K31/497 , A61P31/12
Abstract: Procesos de obtencion de dichos compuestos y composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto alfa-cetoamido enriquecido con deuterio de la formula (1), en donde: D denota un átomo de deuterio; R1 como en formula (2) en donde el anillo es un azaheterociclilo monocíclico opcionalmente sustituido o azaheterociclilo multicíclico opcionalmente sustituido o azaheterociclenilo multicíclico opcionalmente sustituido, en donde la insaturacion está en anillo distal respecto del anillo que lleva el resto R21 y al que está unido el resto -C(O)-N(R2)-CDR3-C(O)-C(O)-NR4R5; R21 es Q3-W3-Q2-W2-Q1; en donde cada uno de W2 y W3 es, de modo independiente, un enlace, -CO-, -CS-, -C(O)N(Q4)-, -CO2-, -O-, -N(Q4)-C(O)-N(Q4)-, - N(Q4)-C(S)-N(Q4)-, -OC(O)NQ4-, -S-, -SO-, -SO2-, -N(Q4)-, -N(Q4)SO2-, -N(Q4)SO2N(Q4)- e hidrogeno cuando cualquiera de W2 y W3 es el grupo terminal; cada uno de Q1, Q2 y Q3 es, de modo independiente, un enlace, un alifático opcionalmente sustituido, un heteroalifático opcionalmente sustituido, un cicloalifático opcionalmente sustituido, un arilo opcionalmente sustituido, un heteroarilo opcionalmente sustituido, un aralquilo opcionalmente sustituido o un heteroaralquilo opcionalmente sustituido; o hidrogeno cuando cualquiera de Q3, Q2 o Q1 es el grupo terminal, con la condicion de que Q2 no sea un enlace cuando tanto W3 como W2 estén presentes; y cada uno de R2, R3 y R4, de modo independiente, es H o un alquilo C1-6; y R5 es H, alquilo, cicloalquilo, arilo opcionalmente sustituido con 1-4 grupos alquilo, alquilarilo, arilo, amino opcionalmente sustituido con 1 o 2 grupos alquilo.
-
公开(公告)号:CA2646229A1
公开(公告)日:2007-09-27
申请号:CA2646229
申请日:2007-03-14
Applicant: VERTEX PHARMA
Inventor: FORSLUND RAYMOND E , JUNG YOUNG CHUN , TANOURY GERALD J , CHEN MINZHANG , MALTAIS FRANCOIS , BENNANI YOUSSEF , ZLOKARNIK GREGOR , PERNI ROBERT B
IPC: C07C231/20 , A61K31/403 , A61K31/422 , A61K31/498 , A61P31/12 , C07C237/04 , C07D209/52 , C07D403/12 , C07D403/14 , C07D498/10
Abstract: This invention relates to a process for preparing a compound of Formula 1 wherein: the carbon atoms alpha and beta to the carboxy group are stereocenters; R 1 is independently H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; R' 1 is deuterium such that the deuterium enrichment is at least 50%; R' 2 is -NHR 2 or -OE; R 2 is H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; and E is C 1-6 alkyl or benzyl; wherein the process comprises the steps of: a) forming a salt of a compound of Formula 1, and b) crystallizing said salt to give a compound of greater than 55% enantiomeric excess.
-
-
-
-
-
-
-